Epidermolysis Bullosa Clinical Trials 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.A Study of PTR-01 in Recessive Dystrophic Epidermolysis Bullosa
Condition: Recessive Dystrophic Epidermolysis Bullosa Intervention: Drug: PTR-01 Sponsor: Phoenix Tissue Repair, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 3, 2020 Category: Research Source Type: clinical trials
The Objective of This Study is to Compare the Efficacy and Safety of Beremagene Geperpavec (B-VEC) Topical Gel With That of Placebo for the Treatment of Dystrophic Epidermolysis Bullosa (DEB).
Conditions: Dystrophic Epidermolysis Bullosa; Recessive Dystrophic Epidermolysis Bullosa; Dominant Dystrophic Epidermolysis Bullosa Interventions: Biological: Topical Beremagene Geperpavec; Other: Placebo Sponsor: Krystal Biotech, Inc. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 29, 2020 Category: Research Source Type: clinical trials
